DHL Supply Chain: Singapore is laser-focused on becoming a global leader in life sciences
DHL Supply Chain has launched a new Pharma Hub in Singapore, a dedicated facility for pharmaceutical logistics. The €10 million facility is part of DHL Group’s €500 million investment into Asia Pacific to bolster its Life Sciences and Healthcare (LSHC) infrastructure across all business units.
This strategic initiative reflects DHL Group’s global focus on the healthcare sector as part of its Strategy 2030, which introduced the new “DHL Health Logistics” sector brand to drive cross-divisional growth. The LSHC sector currently contributes EUR5 billion to DHL’s global revenue, underscoring its significance in the Group’s growth strategy.
“At DHL Supply Chain, we are committed to supporting the rapidly growing LSHC sector in Asia Pacific where there is a growing demand for transformative healthcare solutions due to longer lifespans, personalised treatments and rising consumer expectations. By 2030, the region’s medical market is projected to reach USD138 billion (~€127 billion), reflecting the critical need for resilient and efficient supply chains. As part of DHL Group’s Strategy 2030, we have invested ahead to strengthen our infrastructure and capabilities, ensuring we can meet the evolving and increasingly complex needs of our customers.
Our investment goes beyond building warehouses or expanding networks. It is about building a foundation across all our business units that enables faster, more reliable delivery of life-saving medicines and healthcare products. In a region where healthcare demand is surging, we enable our customers to focus on innovation and patient care. At the same time, we handle the complexities of supply chain management across all logistics touchpoints – from storage, order fulfillment, and distribution to global shipping and last-mile delivery. This is how we deliver real value: by turning challenges into opportunities and ensuring that every link in the healthcare supply chain works seamlessly,” explained Javier Bilbao, CEO, DHL Supply Chain Asia Pacific.
The new 8,200 square meters Pharma Hub at 8 Jurong Pier in Singapore features specialized temperature-controlled zones including ambient (15°C to 25°C) and cold room (2°C to 8°C), ensuring precise storage conditions for sensitive healthcare products. It is Good Manufacturing Practice (GMP) compliant with advanced cold chain infrastructure, including airtight loading docks and dedicated anterooms, ensures uninterrupted temperature stability throughout the logistics process. Future plans are in place to enable pharma related value-added services including redressing activities. Strategically located near Tuas Bio-Medical Park, the Pharma Hub offers seamless connectivity to Changi Airport and Tuas Mega Port, enabling efficient regional and global distribution for pharmaceutical partners.
“Singapore is laser-focused on becoming a global leader in life sciences and medtech innovation. The country’s ambitions are backed by investments, such as a top-up of SGD$3 billion (~€2 billion) in Budget 2025 to attract investments in sectors like semiconductors and life sciences, as well as other key initiatives, including the National Research, Innovation and Enterprise (RIE).
With the new Pharma Hub in Jurong, we have over 36,000 square meters of warehouse space in Singapore dedicated to LSHC operations. Our current operations include being the regional distribution centers for multiple medical device multi-nationals, clinical trials support and other value-added services,” said Eunis Hew, Managing Director, DHL Supply Chain Singapore.
A successful LSHC supply chain requires several critical factors – robust warehouse infrastructure, skilled personnel and innovative solutions. Together, these elements enable DHL Supply Chain to meet the unique demands of the healthcare industry and deliver exceptional value to customers.
